This HTML5 document contains 37 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/drug/DB04160/identifier/chemspider/
n12http://linked.opendata.cz/resource/drugbank/drug/DB04160/identifier/chebi/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n16http://linked.opendata.cz/resource/drugbank/drug/DB04160/identifier/pdb/
n15http://linked.opendata.cz/resource/drugbank/drug/DB04160/identifier/kegg-compound/
n13http://linked.opendata.cz/resource/drugbank/drug/DB04160/identifier/pubchem-compound/
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n14http://linked.opendata.cz/resource/drugbank/drug/DB04160/identifier/pubchem-substance/
n9http://linked.opendata.cz/resource/drugbank/drug/DB04160/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB04160
rdf:type
n3:Drug
n3:group
experimental
owl:sameAs
n6:DB04160 n10:DB04160
dcterms:title
Diphosphate
adms:identifier
n8:559142 n9:DB04160 n12:29888 n13:644102 n14:46507760 n15:C00013 n16:DPO
n3:synthesisReference
Kiyoshi Nakayama, Hiroshi Hagino, "Method for preparing cytidine diphosphate choline." U.S. Patent USRE0288861, issued August 15, 1972.
n3:IUPAC-Name
n4:271B3FED-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B3FF3-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B3FF2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B3FEF-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B3FF0-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B3FF1-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B3FEC-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B3FF9-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B3FFA-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B3FF4-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B3FF5-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B3FF7-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B3FF6-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B3FF8-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
2466-09-3
n3:Bioavailability
n4:271B3FFE-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4000-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4001-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4002-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B3FFD-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B3FFC-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B3FFF-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B3FEE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B3FFB-363D-11E5-9242-09173F13E4C5